Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized adjuvant fotemustine versus surveillance in high-risk choroidal melanoma
2008-005691-27Phase 3Completed
- Sponsor
- Institut Curie
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fotemustine in choroidal melanoma and intraocular melanoma (2 arms), sponsored by Institut Curie. Primary endpoint: Metastasis-free survival rate. Started Mar 2009; status: completed.
02
Drugs
fotemustine
03
Conditions
choroidal melanomaintraocular melanoma
Beyond the preview
Go deeper on 2008-005691-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005691-27.